Table of Pharmacogenomic Biomarkers in Drug LabelingPharmacogenomics can play an important role in identifying responders andnon-responders to medications, avoiding adverse events, and optimizing drug dose.Drug labeling may contain information on genomic biomarkers and can describe:•Drug exposure and clinical response variability•Risk for adverse events•Genotype-specific dosing•Mechanisms of drug action•Polymorphic drug target and disposition genesThe table below lists FDA-approved drugs with pharmacogenomic information in their labeling. The labeling for some, but not all, of the products includes specific actions to be taken based on the biomarker information. Pharmacogenomicinformation can appear in different sections of the labeling depending on the actions.For more information, please refer to the appropriate labeling guidance.Biomarkers in the table include but are not limited to germ-line or somatic genevariants, functional deficiencies, expression changes, and chromosomalabnormalities; selected protein biomarkers that are used to select patients fortreatment are also included.This table does not include non-human genetic biomarkers (e.g., microbial variants that influence sensitivity to antibiotics), or biomarkers that are used solely fordiagnostic purposes (e.g., for genetic diseases) unless they are linked to drug activity or used to identify a specific subset in whom prescribing information differs. Fordrugs that are available in multiple dosage forms, salts, or combinations, a single representative product is listed. In the case of combination products, the singleagent associated with the biomarker is listed unless the agent is only approved as a combination product, in which case all agents are listed.Pharmacogenomic Biomarkers in Drug LabelingDrug TherapeuticArea*Biomarker†Referenced Subgroup‡LabelingSectionsAbacavir InfectiousDiseasesHLA-B HLA-B*5701 allele carriersBoxedWarning,Contraindications, WarningsandPrecautionsAdo-Trastuzum ab Emtansine Oncology ERBB2HER2 proteinoverexpression or geneamplification positiveIndicationsand Usage,Warnings andPrecautions,Area* SectionsAdverseReactions,ClinicalPharmacology, ClinicalStudiesAfatinib Oncology EGFR EGFR exon 19 deletion orexon 21 substitution(L858R) positiveIndicationsand Usage,Dosage andAdministration, AdverseReactions,ClinicalPharmacology, ClinicalStudiesAlectinib Oncology ALK ALK gene rearrangementpositiveIndicationsand Usage,AdverseReactions,ClinicalPharmacology, ClinicalStudiesAlirocumab EndocrinologyLDLRLDL receptor mutationheterozygotesIndicationsand Usage,AdverseReactions,ClinicalStudiesAmitriptyline Psychiatry CYP2D6CYP2D6 poor metabolizers PrecautionsAnastrozole Oncology ESR1, PGR Hormone receptor positive Indications and Usage, Adverse Reactions, Drug Interactions, Clinical StudiesArformoterol (1)Pulmonary UGT1A1UGT1A1 poor metabolizersClinicalPharmacologyArea* SectionsArformoterol (2)Pulmonary CYP2D6CYP2D6 intermediate orpoor metabolizersClinicalPharmacologyAripiprazole Psychiatry CYP2D6CYP2D6 poor metabolizers Dosage and Administratio n, Use in Specific Populations, Drug Interactions, Clinical PharmacologyAripiprazole Lauroxil Psychiatry CYP2D6CYP2D6 poor metabolizersDosage andAdministration, Use inSpecificPopulations,ClinicalPharmacologyArsenic Trioxide Oncology PML-RARAPML-RARα translocationpositiveClinicalPharmacology, Indicationsand UsageAtomoxetine Psychiatry CYP2D6CYP2D6 poor metabolizers Dosage and Administratio n, Warnings and Precautions, Drug Interactions, Clinical PharmacologyAzathioprine RheumatologyTPMTTPMT intermediate or poormetabolizersClinicalPharmacology, Warnings,Precautions,DrugInteractions,AdverseReactions,Dosage andAdministratioArea* SectionsnBelinostat Oncology UGT1A1UGT1A1*28 allelehomozygotesDosage andAdministration, ClinicalPharmacologyBlinatumomab Oncology BCR-ABL1Philadelphia chromosomenegativeIndicationsand Usage,ClinicalStudiesBoceprevir InfectiousDiseasesIFNL3IL28B rs12979860 T allelecarriers (C/T and T/Tgenotype)ClinicalPharmacologyBosutinib Oncology BCR-ABL1Philadelphia chromosomepositiveIndicationsand Usage,AdverseReactions,Use in SpecificPopulations,ClinicalStudiesBrexpiprazole Psychiatry CYP2D6CYP2D6 poor metabolizers Dosage and Administratio n, Drug Interactions, Use in Specific Populations, Clinical PharmacologyBusulfan Oncology BCR-ABL1Philadelphia chromosome negativeClinicalStudiesCabozantinib Oncology RET RET mutation positive Clinical StudiesCapecitabine Oncology DPYD DPD deficient Warnings and Precautions, Patient Counseling InformationCarbamazepin e (1)Neurology HLA-B HLA-B*1502 allele carriersBoxedWarning,Warnings,PrecautionsArea* Sections Carbamazepine (2)Neurology HLA-A HLA-A*3101 allele carriers WarningsCarglumic Acid Inborn ErrorsofMetabolismNAGSN-acetylglutamatesynthase deficientIndicationsand Usage,Warnings andPrecautions,Use in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesCarisoprodol RheumatologyCYP2C19CYP2C19 poormetabolizersUse in SpecificPopulations,ClinicalPharmacologyCarvedilol Cardiology CYP2D6CYP2D6 poor metabolizers Drug Interactions, Clinical PharmacologyCelecoxib RheumatologyCYP2C9CYP2C9 poor metabolizersDosage andAdministration, Use inSpecificPopulations,ClinicalPharmacologyCeritinib Oncology ALK ALK gene rearrangementpositiveIndicationsand Usage,AdverseReactions,ClinicalPharmacology, ClinicalStudiesCetuximab (1)Oncology EGFR EGFR protein expressionpositiveIndicationsand Usage,Dosage andAdministration, WarningsandArea* SectionsPrecautions,AdverseReactions,ClinicalPharmacology, ClinicalStudiesCetuximab (2)Oncology KRAS KRAS codon 12 and 13mutation negativeIndicationsand Usage,Dosage andAdministration, WarningsandPrecautions,AdverseReactions,ClinicalPharmacology, ClinicalStudiesCevimeline Dental CYP2D6CYP2D6 poor metabolizers PrecautionsChloroquine InfectiousDiseasesG6PD G6PD deficient PrecautionsChlorpropamid e EndocrinologyG6PD G6PD deficient PrecautionsCholic Acid Inborn ErrorsofMetabolismAKR1D1,HSD3B7,CYP27A1,AMACR,CYP7A1Bile acid synthesis enzymedeficientIndicationsand Usage,Warnings andPrecautions,AdverseReactions,Use in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesCisplatin Oncology TPMT TPMT intermediate or poor metabolizersAdverseReactionsCitalopram (1)Psychiatry CYP2C19CYP2C19 poormetabolizersClinicalPharmacologyArea* Sections, Warnings,Dosage andAdministrationCitalopram (2)Psychiatry CYP2D6CYP2D6 poor metabolizers Clinical PharmacologyClobazam Neurology CYP2C19CYP2C19 poormetabolizersDosage andAdministration, Use inSpecificPopulations,ClinicalPharmacologyClomipramine Psychiatry CYP2D6CYP2D6 poor metabolizers PrecautionsClopidogrel Cardiology CYP2C19CYP2C19 intermediate orpoor metabolizersBoxedWarning,Dosage andAdministration, WarningsandPrecautions,ClinicalPharmacologyClozapine Psychiatry CYP2D6CYP2D6 poor metabolizers Dosage and Administratio n, Use in Specific Populations, Clinical PharmacologyCobimetinib Oncology BRAF BRAF V600E/K mutationpositiveIndicationsand Usage,Dosage andAdministration, AdverseReactions,ClinicalPharmacology, ClinicalStudiesCodeine Anesthesiolo CYP2D6CYP2D6 ultrarapid BoxedArea* Sectionsgy metabolizers Warning,Warnings andPrecautions,Use in SpecificPopulations,PatientCounselingInformationCrizotinib Oncology ALK ALK gene rearrangementpositiveIndicationsand Usage,Dosage andAdministration, AdverseReactions,ClinicalPharmacology, ClinicalStudiesDabrafenib (1)Oncology BRAF BRAF V600E/K mutationpositiveIndicationsand Usage,Dosage andAdministration, WarningsandPrecautions,AdverseReactions,ClinicalPharmacology, ClinicalStudies,PatientCounselingInformationDabrafenib (2)Oncology G6PD G6PD deficient Warnings and Precautions, Adverse Reactions, Patient Counseling InformationArea* SectionsDapsone (1)Dermatology G6PD G6PD deficient Warnings and Precautions, Use in Specific Populations, Patient Counseling InformationDapsone (2)InfectiousDiseasesG6PD G6PD deficientPrecautions,AdverseReactions,OverdosageDasatinib Oncology BCR-ABL1Philadelphia chromosomepositive, T315I mutationpositiveIndicationsand Usage,Dosage andAdministration, WarningsandPrecautions,AdverseReactions,ClinicalPharmacology, ClinicalStudiesDenileukin Diftitox Oncology IL2RA CD25 antigen positiveIndicationsand Usage,Warnings andPrecautions,ClinicalStudiesDesipramine Psychiatry CYP2D6CYP2D6 poor metabolizers PrecautionsDexlansoprazol e GastroenterologyCYP2C19CYP2C19 poormetabolizersDrugInteractions,ClinicalPharmacologyDextromethorphan and Quinidine Neurology CYP2D6CYP2D6 poor metabolizersWarnings andPrecautions,ClinicalPharmacologyDiazepam Neurology CYP2C19CYP2C19 poormetabolizersClinicalPharmacologyArea* SectionsDinutuximab Oncology MYCN MYCN amplificationpositiveClinicalStudiesDolutegravir InfectiousDiseasesUGT1A1UGT1A1 poor metabolizersClinicalPharmacologyDoxepin (1)Psychiatry CYP2D6CYP2D6 poor metabolizers Clinical PharmacologyDoxepin (2)Psychiatry CYP2C19CYP2C19 poormetabolizersClinicalPharmacologyDrospirenoneand Ethinyl Estradiol Gynecology CYP2C19CYP2C19 intermediatemetabolizersClinicalPharmacologyEliglustat Inborn ErrorsofMetabolismCYP2D6CYP2D6 ultrarapid,intermediate or poormetabolizersIndicationsand Usage,Dosage andAdministration,Contraindications, WarningsandPrecautions,DrugInteractions,Use in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesElosulfase Inborn ErrorsofMetabolismGALNSN-acetylgalactosamine-6-sulfatase deficientIndicationsand Usage,Warnings andPrecautions,Use in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesEltrombopag (1)Hematology F5Factor V Leiden carriersWarnings andPrecautionsEltrombopag Hematology SERPINC1Antithrombin III deficient Warnings andArea* Sections (2)PrecautionsErlotinib (1)Oncology EGFR EGFR protein expression positiveClinicalStudiesErlotinib (2)Oncology EGFR EGFR exon 19 deletion orexon 21 substitution(L858R) positiveIndicationsand Usage,Dosage andAdministration, AdverseReactions,ClinicalPharmacology, ClinicalStudiesEscitalopram (1)Psychiatry CYP2D6CYP2D6 poor metabolizersDrugInteractionsEscitalopram (2)Psychiatry CYP2C19CYP2C19 poormetabolizersAdverseReactionsEsomeprazole GastroenterologyCYP2C19CYP2C19 poormetabolizersDrugInteractions,ClinicalPharmacologyEverolimus (1)Oncology ERBB2HER2 proteinoverexpression negativeIndicationsand Usage,Dosage andAdministration, WarningsandPrecautions,AdverseReactions,DrugInteractions,Use in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesEverolimus (2)Oncology ESR1Estrogen receptor positive Clinical StudiesEvolocumab Endocrinolog LDLR LDL receptor mutation IndicationsArea* Sectionsy heterozygotes andhomozygotes and Usage, Dosage and Administratio n, Adverse Reactions, Use in Specific Populations, Clinical StudiesExemestane (1)Oncology ESR1Estrogen receptor positiveIndicationsand Usage,Dosage andAdministration, ClinicalStudiesExemestane (2)Oncology PGRProgesterone receptorpositiveClinicalStudiesFesoterodine Urology CYP2D6CYP2D6 poor metabolizers Drug Interactions, Clinical PharmacologyFluorouracil (1)Dermatology DPYD DPD deficient Contraindicati ons, WarningsFluorouracil (2)Oncology DPYD DPD deficient WarningsFluoxetine Psychiatry CYP2D6CYP2D6 poor metabolizers Warnings and Precautions, Drug Interactions, Clinical PharmacologyFlurbiprofen RheumatologyCYP2C9CYP2C9 poor metabolizersClinicalPharmacologyFluvoxamine Psychiatry CYP2D6CYP2D6 poor metabolizers Drug InteractionsFulvestrant Oncology ESR1, PGR Hormone receptor positive Indications and Usage, Clinical Pharmacology , Clinical StudiesArea* SectionsGalantamine Neurology CYP2D6CYP2D6 poor metabolizers Clinical PharmacologyGefitinib Oncology EGFR EGFR exon 19 deletions orexon 21 substitution(L858R) mutation positiveIndicationsand Usage,Dosage andAdministration, ClinicalPharmacology, ClinicalStudiesGlimepiride EndocrinologyG6PD G6PD deficientWarnings andPrecautions,AdverseReactionsGlipizide EndocrinologyG6PD G6PD deficient PrecautionsGlyburide EndocrinologyG6PD G6PD deficient PrecautionsHydralazine Cardiology NAT1-2NAT 1-2 slow acetylators Clinical PharmacologyIbrutinib Oncology del (17p)Chromosome 17p deletionpositiveIndicationsand Usage,ClinicalStudiesIloperidone Psychiatry CYP2D6CYP2D6 poor metabolizers Dosage and Administratio n, Warnings and Precautions, Drug Interactions, Clinical PharmacologyImatinib (1)Oncology KIT KIT protein expressionpositive, c-KIT D816Vmutation negativeIndicationsand Usage,Dosage andAdministration, WarningsandPrecautions,AdverseArea* SectionsReactions,Use in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesImatinib (2)Oncology BCR-ABL1Philadelphia chromosomepositiveIndicationsand Usage,Dosage andAdministration, WarningsandPrecautions,AdverseReactions,Use in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesImatinib (3)Oncology PDGFRB PDGFR generearrangement positiveIndicationsand Usage,Dosage andAdministration, ClinicalStudiesImatinib (4)Oncology FIP1L1-PDGFRAFIP1L1-PDGFRα fusionkinase (or CHIC2 deletion)positiveIndicationsand Usage,Dosage andAdministration, ClinicalStudiesImipramine Psychiatry CYP2D6CYP2D6 poor metabolizers PrecautionsIndacaterol Pulmonary UGT1A1UGT1A1*28 allelehomozygotesClinicalPharmacologyIrinotecan Oncology UGT1A1UGT1A1*28 allele carriers Dosage and Administratio n, Warnings andArea* SectionsPrecautions,ClinicalPharmacologyIvacaftor Pulmonary CFTR CFTR G551D, G1244E,G1349D, G178R, G551S,S1251N, S1255P, S549N,S549R, R117H mutationpositive, F508del mutation homozygotesIndicationsand Usage,AdverseReactions,Use in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesLacosamide Neurology CYP2C19CYP2C19 poormetabolizersClinicalPharmacologyLansoprazole GastroenterologyCYP2C19CYP2C19 intermediate orpoor metabolizersDrugInteractionsLapatinib (1)Oncology ERBB2HER2 proteinoverexpression positiveIndicationsand Usage,Dosage andAdministration, AdverseReactions,Use in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesLapatinib (2)Oncology HLA-DQA1,HLA-DRB1HLA-DQA1*0201 orHLA-DRB1*0701 allelecarriersClinicalPharmacologyLenalidomide Hematology del (5q)Chromosome 5q deletionpositiveBoxedWarning,Indicationsand Usage,AdverseReactions,Use in SpecificPopulations,ClinicalArea* SectionsStudiesLesinurad RheumatologyCYP2C9CYP2C9 poor metabolizersClinicalPharmacologyLetrozole Oncology ESR1, PGR Hormone receptor positive Indications and Usage, Adverse Reactions, Clinical Pharmacology , Clinical StudiesLomitapide EndocrinologyLDLRLDL receptor mutationhomozygotesIndication andUsage,Warnings andPrecautions,AdverseReactions,ClinicalStudiesIvacaftor and Lumacaftor Pulmonary CFTRCFTR F508del mutationhomozygotesIndicationsand Usage,AdverseReactions,ClinicalPharmacology, ClinicalStudiesMafenide InfectiousDiseasesG6PD G6PD deficientWarnings,AdverseReactionsMercaptopurin e Oncology TPMTTPMT intermediate or poormetabolizersClinicalPharmacology, Warnings,Precautions,AdverseReactions,Dosage andAdministrationMethyleneBlueHematology G6PD G6PD deficient PrecautionsArea* SectionsMetocloprami de (1)GastroenterologyCYB5R1-4NADH cytochrome b5reductase deficientPrecautionsMetocloprami de (2)GastroenterologyG6PD G6PD deficient PrecautionsMetoprolol Cardiology CYP2D6CYP2D6 poor metabolizers Clinical PharmacologyMipomersen EndocrinologyLDLRLDL receptor mutationheterozygotes andhomozygotesIndicationsand Usage,Warnings andPrecautions,AdverseReactions,Use in SpecificPopulations,ClinicalStudiesModafinil Psychiatry CYP2D6CYP2D6 poor metabolizers Clinical Pharmacology , PrecautionsMycophenolic Acid TransplantationHPRT1HGPRT deficientWarnings andPrecautionsNalidixic Acid InfectiousDiseasesG6PD G6PD deficientPrecautions,AdverseReactionsNefazodone Psychiatry CYP2D6CYP2D6 poor metabolizers PrecautionsNilotinib (1)Oncology BCR-ABL1Philadelphia chromosomepositiveIndicationsand Usage,Dosage andAdministration, AdverseReactions,Use in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesNilotinib (2)Oncology UGT1A1UGT1A1*28 allelehomozygotesClinicalPharmacologyNitrofurantoin Infectious G6PD G6PD deficient Warnings,Area* Sections Diseases AdverseReactionsNivolumab (1)Oncology BRAF BRAF V600 mutationpositiveIndicationsand Usage,AdverseReactions,ClinicalStudiesNivolumab (2)Oncology CD274PD-L1 protein expressionpositiveClinicalPharmacologyNortriptyline Psychiatry CYP2D6CYP2D6 poor metabolizers PrecautionsObinutuzumab Oncology MS4A1CD20 antigen positive Clinical StudiesOlaparib Oncology BRCA1-2BRCA1-2 mutation positive Indications and Usage, Dosage and Administratio n, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology , Clinical StudiesOmacetaxine Oncology BCR-ABL1Philadelphia chromosomepositiveClinicalPharmacology, ClinicalStudiesOmbitasvir,Paritaprevir, Ritonavir, and Dasabuvir InfectiousDiseasesIFNL3IL28B rs12979860 T allelecarriers (non-C/Cgenotype)ClinicalStudiesOmeprazole GastroenterologyCYP2C19CYP2C19 poormetabolizersDrugInteractionsOsimertinib Oncology EGFR EGFR T790M mutationpositiveIndicationsand Usage,Dosage andAdministration, AdverseArea* SectionsReactions,ClinicalPharmacology, ClinicalStudiesPalbociclib (1)Oncology ESR1Estrogen receptor positive Indications and Usage, Adverse Reactions, Clinical Pharmacology , Clinical StudiesPalbociclib (2)Oncology ERBB2HER2 proteinoverexpression negativeIndicationsand Usage,AdverseReactions,ClinicalStudiesPalonosetron GastroenterologyCYP2D6CYP2D6 poor metabolizersClinicalPharmacologyPanitumumab (1)Oncology EGFREGFR protein expressionpositiveClinicalPharmacology, ClinicalStudiesPanitumumab (2)Oncology KRASKRAS codon 12 and 13mutation negativeIndicationsand Usage,Dosage andAdministration, WarningsandPrecautions,AdverseReactions,ClinicalPharmacology, ClinicalStudiesPantoprazole GastroenterologyCYP2C19CYP2C19 poormetabolizersClinicalPharmacologyParathyroid Inborn Errors CASR Calcium sensing receptor IndicationsArea* SectionsHormone ofMetabolism mutation positive and Usage,ClinicalStudiesParoxetine Psychiatry CYP2D6CYP2D6 extensive and poor metabolizersDrugInteractions,ClinicalPharmacologyPazopanib Oncology UGT1A1UGT1A1*28 allelehomozygotesClinicalPharmacology, WarningsandPrecautionsPEG-3350, Sodium Sulfate, SodiumChloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid GastroenterologyG6PD G6PD deficientWarnings andPrecautionsPegloticase RheumatologyG6PD G6PD deficientContraindications, PatientCounselingInformationPembrolizuma b (1)Oncology BRAFBRAF V600 mutationpositiveIndicationsand Usage,AdverseReactions,ClinicalStudiesPembrolizuma b (2)Oncology CD274PD-L1 protein expressionpositiveIndicationsand Usage,Dosage andAdministration, ClinicalPharmacology, ClinicalStudiesPerphenazine Psychiatry CYP2D6CYP2D6 poor metabolizers ClinicalArea* SectionsPharmacology, PrecautionsPertuzumab Oncology ERBB2HER2 proteinoverexpression positiveIndicationsand Usage,Warnings andPrecautions,AdverseReactions,ClinicalPharmacology, ClinicalStudiesPhenytoin (1)Neurology CYP2C9CYP2C9 variant allelecarriersClinicalPharmacologyPhenytoin (2)Neurology CYP2C19CYP2C19 variant allelecarriersClinicalPharmacologyPhenytoin (3)Neurology HLA-B HLA-B*1502 allele carriers WarningsPimozide Psychiatry CYP2D6CYP2D6 poor metabolizers Precautions, Dosage and Administratio nPonatinib Oncology BCR-ABL1Philadelphia chromosomepositive; T315I mutationpositiveIndicationsand Usage,Warnings andPrecautions,AdverseReactions,Use in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesPrasugrel (1)Cardiology CYP2C19CYP2C19 poormetabolizersUse in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesPrasugrel (2)Cardiology CYP2C9CYP2C9 variant allelecarriersUse in SpecificPopulations,Area* SectionsClinicalPharmacology, ClinicalStudiesPrasugrel (3)Cardiology CYP3A5CYP3A5 variant allelecarriersUse in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesPrasugrel (4)Cardiology CYP2B6CYP2B6 variant allelecarriersUse in SpecificPopulations,ClinicalPharmacology, ClinicalStudiesPravastatin EndocrinologyLDLRLDL receptor mutationheterozygotes andhomozygotesIndicationsand Usage,Use in SpecificPopulations,ClinicalStudiesPrilocaine and Lidocaine (1)AnesthesiologyCYB5R1-4NADH cytochrome b5reductase deficientWarnings andPrecautionsPrilocaine and Lidocaine (2)AnesthesiologyG6PD G6PD deficientWarnings andPrecautionsPrimaquine InfectiousDiseasesG6PD G6PD deficientWarnings andPrecautions,AdverseReactionsPropafenone Cardiology CYP2D6CYP2D6 poor metabolizers Dosage and Administratio n, Warnings and Precautions, Clinical PharmacologyPropranolol Cardiology CYP2D6CYP2D6 poor metabolizers Clinical PharmacologyProtriptyline Psychiatry CYP2D6CYP2D6 poor metabolizers PrecautionsArea*SectionsQuinidine Cardiology CYP2D6 CYP2D6 poor metabolizers PrecautionsQuinine Sulfate (1) Infectious Diseases G6PD G6PD deficientContraindications Quinine Sulfate (2) Infectious Diseases CYP2D6CYP2D6 poor metabolizersDrugInteractions RabeprazoleGastroenterologyCYP2C19CYP2C19 poor metabolizers DrugInteractions, ClinicalPharmacology Rasburicase (1) Oncology G6PDG6PD deficientBoxed Warning, Contraindications, Warnings andPrecautions Rasburicase (2) Oncology CYB5R1-4NADH cytochrome b5 reductase deficient BoxedWarning, Warnings andPrecautions Rifampin,Isoniazid, andPyrazinamide InfectiousDiseasesNAT1-2NAT 1-2 slow acetylatorsClinicalPharmacology, Adverse Reactions RisperidonePsychiatryCYP2D6CYP2D6 poor metabolizersClinicalPharmacology Rituximab Oncology MS4A1CD20 antigen positiveIndications and Usage, Dosage and Administratio n, Adverse Reactions,Use in Specific Populations, ClinicalPharmacology , Clinical StudiesRosuvastatin (1) EndocrinologySLCO1B1SLCO1B1 reduced function allele homozygotes Clinical Pharmacology Rosuvastatin Endocrinolog LDLRLDL receptor mutation IndicationsArea* Sections(2)y heterozygotes andhomozygotes and Usage, Dosage and Administratio n, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology , Clinical StudiesSevoflurane AnesthesiologyRYR1Ryanodine receptormutation positiveWarningsSimeprevir InfectiousDiseasesIFNL3IL28B rs12979860 T allelecarriers (non-C/Cgenotype)ClinicalPharmacology, ClinicalStudiesSodium Nitrite Toxicology G6PD G6PD deficient Warnings and PrecautionsSodium Phenylacetate and Sodium Benzoate Inborn ErrorsofMetabolismNAGS,CPS1, ASS1,OTC, ASL,ABL2Urea cycle enzymedeficientIndicationsand Usage,Dosage andAdministration, WarningsandPrecautions,AdverseReactions,DrugInteractions,Use in SpecificPopulations,Overdosage,ClinicalPharmacology, ClinicalStudiesSofosbuvir InfectiousDiseasesIFNL3IL28B rs12979860 T allelecarriers (non-C/Cgenotype)ClinicalStudiesSuccimer Hematology G6PD G6PD deficient ClinicalArea* SectionsPharmacologySulfamethoxaz ole and Trimethoprim InfectiousDiseasesG6PD G6PD deficient PrecautionsTamoxifen (1)Oncology ESR1, PGR Hormone receptor positive Clinical Pharmacology , Indications and Usage, Precautions, Adverse ReactionsTamoxifen (2)Oncology F5Factor V Leiden carriers WarningsTamoxifen (3)Oncology F2Prothrombin G20210Aallele positiveWarningsTelaprevir InfectiousDiseasesIFNL3IL28B rs12979860 T allelecarriers (C/T and T/Tgenotype)ClinicalPharmacology, ClinicalStudiesTetrabenazine Neurology CYP2D6CYP2D6 poor metabolizers Dosage and Administratio n, Warnings and Precautions, Use in Specific Populations, Clinical PharmacologyThioguanine Oncology TPMT TPMT intermediate or poor metabolizersWarnings,Precautions,Dosage andAdministrationThioridazine Psychiatry CYP2D6CYP2D6 poor metabolizers Contraindicati ons, Warnings, PrecautionsTicagrelor Cardiology CYP2C19CYP2C19 poormetabolizersClinicalStudiesTolterodine Urology CYP2D6CYP2D6 poor metabolizers Warnings and Precautions,。
